Gynäkologie Essen: Klinikdirektor Univ.-Prof. Dr. Dr. med. K. Rainer Kimmig

Literaturverzeichnis Rainer Kimmig 1983-2015

(Quelle „research gate“, Stand Dezember 2015)

Gesamtzahl der Publikationen: 447
Kumulativer Impact Factor (IF): 1177,47

Auszug von 2011-2015:

2015

1. Buderath P, Kimmig R.
Oncological outcomes of robotic-assisted radical hysterectomy.
Minerva Ginecol. 2015 Nov 25.

2. Kimmig R, Iannaccone A, Aktas B, Buderath P, Heubner M.
Embryologically based radical hysterectomy as peritoneal mesometrial resection (PMMR) with pelvic and para-aortic lymphadenectomy for loco-regional tumor control in endometrial cancer: first evidence for efficacy.
Arch Gynecol Obstet. 2015 Nov 23. DOI 10.1007/s00404-015-3956-y.

3. Rezai M, Kraemer S, Kimmig R, Kern P.
Breast conservative surgery and local recurrence.
Breast. 2015 Nov.;24 Suppl 2:S100-7.

4. Kern P, VON Minckwitz G, Puetter C, Pavlidou S, Flach A, Kimmig R, Rezai M.
Prognostic Impact of Residual Disease After Neoadjuvant Chemotherapy in 648 Patients with Triple-negative Breast Cancer.
Anticancer Res. 2015 Oct;35(10): 5479-84.

5. van Dam PA, Tomatis M, Marotti L, Heil J, Wilson R, Rosselli Del Turco M, Mayr C, Costa A, Danei M, Denk A, Emons G, Friedrichs K, Harbeck N, Kiechle M, Koheler U, Kuemmel S, Maass N, Marth C, Prové A, Kimmig R, Rageth C, Regolo L, Salehi L, Sarlos D, Singer C, Sohn C, Staelens G, Tinterri C, Ponti A; eusomaDB Working Group:; eusomaDB Working Group.
The effect of EUSOMA certification on quality of breast cancer care.
Eur J Surg Oncol. 2015 Oct;41(10):1423-9.

6. Köninger A, Schmidt B, Mach P, Damaske D, Nießen S, Kimmig R, Strowitzki T, Gellhaus A.
Anti-Mullerian-Hormone during pregnancy and peripartum using the new Beckman Coulter AMH Gen II Assay.
Reprod Biol Endocrinol. 2015 Aug 7;13:86. doi: 10.1186/s12958-015-0082-4.

7. Kern P, Kalisch A, von Minckwitz G, Pütter C, Kolberg HC, Pott D, Kurbacher C, Rezai M, Kimmig R.
Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of rates of pathologic complete response and survival.
J Chemother. 2015 Aug 4:1973947815Y0000000061. [Epub ahead of print]

8. Zola P, Macchi C, Cibula D, Colombo N, Kimmig R, Maggino T, Reed N, Kesic V.
Follow-up in Gynecological Malignancies: A State of Art.
Int J Gynecol Cancer. 2015 Sep;25(7):1151-64.

9. Kern P, Zarth F, Kimmig R, Rezai M.
Impact of Age, Obesity and Smoking on Patient Satisfaction with Breast Implant Surgery - A Unicentric Analysis of 318 Implant Reconstructions after Mastectomy.
Geburtshilfe Frauenheilkd. 2015 Jun;75(6):597-604.

10. Heubner M, Wimberger P, Kasimir-Bauer S, Singer BB, Ruf P, Kimmig R, Siffert W.
Single nucleotide polymorphisms of the EpCAM-coding gene TACSTD1 in patients with ovarian cancer and their potential translational aspects.
Arch Gynecol Obstet. 2015 Dec;292(6):1367-72

11. Bachmann HS, Meier W, du Bois A, Kimmig R, Kuhlmann JD, Siffert W, Sehouli J, Wollschlaeger K, Huober J, Hillemanns P, Burges A, Schmalfeldt B, Aminossadati B, Wimberger P.
The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.
Br J Clin Pharmacol. 2015 10.1111/bcp.12688. Epub 2015 Jul 22..

12. Otto T, Gellhaus A, Lüschen N, Scheidler J, Bendix I, Dunk C, Wolf N, Lennartz K, Köninger A, Schmidt M, Kimmig R, Fandrey J, Winterhager E.
Oxygen Sensitivity of Placental Trophoblast Connexins 43 and 46: A Role in Preeclampsia?
J Cell Biochem. 2015 Dec;116(12):2924-37. doi: 10.1002/jcb.25240.

13. Rezai M, Kellersmann S, Knispel S, Lax H, Kimmig R, Kern P.
Translating the concept of intrinsic subtypes into an oncoplastic cohort of more than 1000 patients - predictors of recurrence and survival.
Breast. 2015 Aug;24(4):384-90.

14. Hoffmann O, Schroer-Zuendorf IA, Kasimir-Bauer S, Oberhoff C, Kimmig R, Heubner M.
Evaluation of the prognostic significance of disseminated tumor cells in the bone marrow of primary, non-metastatic breast cancer patients after a 7-year follow-up.
Arch Gynecol Obstet. 2015 Nov;292(5):1117-25. doi: 10.1007/s00404-015-3748-4. Epub 2015 May 19.

15. Birdir C, Janssen K, Stanescu AD, Enekwe A, Kasimir-Bauer S, Gellhaus A, Kimmig R, Köninger A.
Maternal serum copeptin, MR-proANP and procalcitonin levels at 11-13 weeks gestation in the prediction of preeclampsia.
Arch Gynecol Obstet. 2015 Nov;292(5):1033-42. doi: 10.1007/s00404-015-3745-7. Epub 2015 May 15.

16. Mach P, Gellhaus A, Wicherek L, Schmidt B, Kimmig R, Kasimir-Bauer S, Köninger A.
Changes in the Blood Serum Levels of the Costimulatory Soluble B7-H4 Molecule in Pregnant Women During the Peripartal Phase.
Am J Reprod Immunol. 2015 Sep;74(3):209-15

17. Rezai M, Knispel S, Kellersmann S, Lax H, Kimmig R, Kern P.
Systematization of Oncoplastic Surgery: Selection of Surgical Techniques and Patient-Reported Outcome in a Cohort of 1,035 Patients.
Ann Surg Oncol. 2015 Feb 12.

18. Köninger A, Koch L, Enekwe A, Birdir C, Kasimir-Bauer S, Kimmig R, Strowitzki T, Schmidt B.
Change of anti-Mullerian-hormone levels during follicular phase in PCOS patients.
Gynecol Endocrinol 2015 Jan;31(1):26-30.

19. Tewes M, Kasimir-Bauer S, Welt A, Schuler M, Kimmig R, Aktas B.
Detection of disseminated tumor cells in bone marrow and circulating tumor cells in blood of patients with early-stage male breast cancer.
J Cancer Res Clin Oncol.. 2015 Jan;141(1):87-92.


2014

20. Söhngen L, Schmidt M, Wimberger P, Kimmig R, Grümmer R.
Additional B-cell deficiency does not affect growth and angiogenesis of ectopic human endometrium in T-cell-deficient endometriosis mouse models during long-term culture.
J Reprod Immunol. 2014 Dec;106:50-7.

21. du Bois A, Floquet A, Kim JW, Rau J, Del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P.
Incorporation of pazopanib in maintenance therapy of ovarian cancer.
J Clin Oncol. 2014 Oct 20;32(30):3374-82.

22. Kimmig, R.
Innovationen in der operativen Therapie von Genitalkarzinomen
Der Gynäkologe, 2014 12;932-941

23. Köninger A, Koch L, Edimiris P, Nießen S, Kasimir-Bauer S, Kimmig R, Strowitzki T, Schmidt B.
Intraindividual right-left comparison of sonographic features in polycystic ovary syndrome (PCOS) diagnosis.
Eur J Obstet Gynecol Reprod Biol. 2014 Oct;181:124-9.

24. Aktas, B. Hoffmann, O., Kimmig R.
Die junge Mammakarzinom-Patientin: Was ist zu beachten?
Ärztliches Journal Onkologie 2014;5:20-25

25. Kuhlmann JD, Wimberger P, Bankfalvi A, Keller T, Schöler S, Aktas B, Buderath P, Hauch S, Otterbach F, Kimmig R, Kasimir-Bauer S.
ERCC1-Positive Circulating Tumor Cells in the Blood of Ovarian Cancer Patients as a Predictive Biomarker for Platinum Resistance.
Clin Chem. 2014 Oct;60(10):1282-9.

26. Köninger A, Koch L, Edimiris P, Enekwe A, Nagarajah J, Kasimir-Bauer S, Kimmig R, Strowitzki T, Schmidt B.
Anti-Mullerian Hormone: an indicator for the severity of polycystic ovarian syndrome.
Arch Gynecol Obstet. 2014 Nov;290(5):1023-30.

27. Heubner M, Kimmig R, Aktas B, Siffert W, Frey UH
The haplotype of three polymorphisms in the SATB1 promoter region impacts survival in breast cancer patients..
Oncol Lett. 2014 Jun;7(6):2007-2012. 2014 Mar 20.

28. Köninger A, Edimiris P, Koch L, Enekwe A, Lamina C, Kasimir-Bauer S, Kimmig R, Dieplinger H.
Serum concentrations of afamin are elevated in patients with polycystic ovary syndrome.
Endocr Connect. 2014 Sep;3(3):120-6.

29. Wimberger P, Chebouti I, Kasimir-Bauer S, Lachmann R, Kuhlisch E, Kimmig R, Süleyman E, Kuhlmann JD.
Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevance.
Gynecol Oncol. 2014 Jun;133(3):467-72

30. Köninger A, Sauter L, Edimiris P, Kasimir-Bauer S, Kimmig R, Strowitzki T, Schmidt B.
Predictive markers for the FSH sensitivity of women with polycystic ovarian syndrome.
Hum Reprod. 2014 Mar;29(3):518-24
.
31. R. Kimmig, N. Maass
Laparoskopie in der gynäkologischen Onkologie
Der Gynäkologe 2014 März: 47, 3: 165-166

32. R. Kimmig, N. Maass
Laparoskopie und roboterassistierte Chirurgie in der Gynäkologie
Der Gynäkologe 2014 März: 47, 3: 164

33. Kuhlmann JD, Baraniskin A, Hahn SA, Mosel F, Bredemeier M, Wimberger P, Kimmig R, Kasimir-Bauer S.
Circulating u2 small nuclear RNA fragments as a novel diagnostic tool for patients with epithelial ovarian cancer.
Clin Chem. 2014 Jan;60(1):206-13

34. Heitz F, Amant F, Fotopoulou C, Battista MJ, Wimberger P, Traut A, Fisseler-Eckhoff A, Harter P, Vandenput I, Sehouli J, Schmidt M, Kimmig R, du Bois R, du Bois A.
Synchronous ovarian and endometrial cancer-an international multicenter case--control study.
Int J Gynecol Cancer. 2014 Jan;24(1):54-60.

35. Köninger A, Sauter L, Edimiris P, Kasimir-Bauer S, Kimmig R, Strowitzki T, Schmidt B.
Predictive markers for the FSH sensitivity of women with polycystic ovarian syndrome.
Hum Reprod. 2014 Jan 12.


2013

36. Aktas B, Bankfalvi A, Heubner M, Kimmig R, Kasimir-Bauer S.
Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX®, clinicopathological markers and tumor cell dissemination in the blood and bone marrow.
Mol Clin Oncol. 2013 Nov;1(6):

37. Kern P, Kalisch A, Kolberg HC, Kimmig R, Otterbach F, von Minckwitz G, Sikov WM, Pott D, Kurbacher C.
Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of feasibility and rates of pathologic complete response
Chemotherapy. 2013;59(5):387-94.

38. Welt A, Tewes M, Aktas B, Hoffmann O, Wiesweg M, Ting S, Reis H, Worm K, Richly H, Hense J, Palmer MR, Lee BH, Wendling J, Kossow J, Scheulen ME, Lehnerdt C, Kohl M, Derks C, Skottky S, Haus U, Schmid KW, Kimmig R, Schuler M, Kasper S.
Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients.
Breast Cancer Res Treat. 2013 Oct 12.

39. Kimmig, R., Buderath,P., Aktas, B., Heubner, M.
Peritoneale mesometriale Resektion (PMMR als Kompartiment-basierte Operation)
Der Gynäkologe 2013 Oct.: 751-56

40. 2.Harter P, Sehouli J, Kimmig R, Rau J, Hilpert F, Kurzeder C, Elser G, du Bois A.
Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13).
Invest New Drugs. 2013 Sep 5.

41. Kimmig R, Aktas B, Buderath P, Wimberger P, Iannaccone A, Heubner M.
Definition of compartment-based radical surgery in uterine cancer: modified radical hysterectomy in intermediate/high-risk endometrial cancer using peritoneal mesometrial resection (PMMR) by M Hockel translated to robotic surgery.
World J Surg Oncol. 2013 Aug 16;11(1):198.

42. Kimmig R, Wimberger P, Buderath P, Aktas B, Iannaccone A, Heubner M.
Definition of compartment-based radical surgery in uterine cancer: radical hysterectomy in cervical cancer as 'total mesometrial resection (TMMR)' by Michael Hockel translated to robotic surgery (rTMMR).
World J Surg Oncol. 2013 Aug 26;11(1):211.


43. R. Kimmig, B. Aktas, M. Heubner
Endometriumkarzinom - operative Strategie und Adjuvanz
Der Gynäkologe 2013;Mai,339-344

44. Köninger A, Kauth A, Schmidt B, Schmidt M, Yerlikaya G, Kasimir-Bauer S, Kimmig R, Birdir C.
Anti-Mullerian-hormone levels during pregnancy and postpartum.
Reprod Biol Endocrinol. 2013 Jul 11;11(1):60

45. Aktas B, Kasimir-Bauer S, Lehmann N, Kimmig R, Tewes M.
Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer.
Oncol Rep. 2013 Jul;30(1):441-7.

46. Fehm T, Banys M, Rack B, Janni W, Marth C, Blassl C, Hartkopf A, Trope C, Kimmig R, Krawczyk N, Wallwiener D, Wimberger P, Kasimir-Bauer S.
Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone marrow of patients with ovarian cancer.
Int J Gynecol Cancer. 2013 Jun;23(5):839-45

47. Han SN, Kesic VI, Van Calsteren K, Petkovic S, Amant F; Kimmig R., ESGO ‘Cancer in Pregnancy’ Task Force.
Cancer in pregnancy: a survey of current clinical practice.
Eur J Obstet Gynecol Reprod Biol. 2013;167(1): 18-23 Mar.

48. Kimmig R., Iannaccone, A., Buderath P, Aktas B., Wimberger P., Heubner M.
Definition of Compartment Based Radical Surgery in Uterine Cancer-Part I: Therapeutic Pelvic and Periaortic Lymphadenectomy by Michael Höckel Translated to Robotic Surgery
Hindawi Publ. 1-17 Clinical Study 2013 Jan.; 19

49. Aktas B, Kasimir-Bauer S, Wimberger P, Kimmig R, Heubner M.
Utility of Mesothelin, L1CAM and Afamin as Biomarkers in Primary Ovarian Cancer.
Anticancer Res. 2013 Jan;33(1):329-36.


2012

50. Steiner, E, Juhasz-Bosz, I, Emons, G. Kimmig R, Mallmann P
Transvaginal Ultrasound for Endometrial Carcinoma Screening - Current Evidence-based Data.
Geburtshilfe Frauenheilkd. 2012;72(12): 1088-1091

51. Gottschalk N, Kimmig R, Lang S, Singh M, Brandau S.
Anti-Epidermal Growth Factor Receptor (EGFR) Antibodies Overcome Resistance of Ovarian Cancer Cells to Targeted Therapy and Natural Cytotoxicity.
Int J Mol Sci. 2012;13(9):12000-16.

52. Kasimir-Bauer, S., Wimberger P., Kimmig R.
Schlafende Tumorzellen - Widerstandskämpfer der gynäkologischen Tumorerkrankungen
UNIKATE 11;2012:81-89

53. Mikat B, Gellhaus A, Wagner N, Birdir C, Kimmig R, Köninger A.
Early detection of maternal risk for preeclampsia.
Obstet Gynecol. 2012;2012:172808.

54. Riegger C, Koeninger A, Hartung V, Otterbach F, Kimmig R, Forsting M, Bockisch A, Antoch G, Heusner TA.
Comparison of the diagnostic value of FDG-PET/CT and axillary ultrasound for the detection of lymph node metastases in breast cancer patients.
Acta Radiol. 2012 Dec 1;53(10):1092-8.

55. Gottschalk N, Lang S, Kimmig R, Singh M, Brandau S.
Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines.
BMC Cancer. 2012 Oct 4;12(1):451.

56. Garcia-Etienne CA, Tomatis M, Heil J, Friedrichs K, Kreienberg R, Denk A, Kiechle M, Lorenz-Salehi F, Kimmig R, Emons G, Danaei M, Heyl V, Heindrichs U, Rageth CJ, Janni W, Marotti L, Turco MR, Ponti A; Eusoma DB Working Group.
Mastectomy trends for early-stage breast cancer: A report from the EUSOMA multi-institutional European database.
Eur J Cancer. 2012 Sep. 48 (13):1947-56.

57. Kuhlmann JD, Schwarzenbach H, Wimberger P, Poetsch M, Kimmig R, Kasimir-Bauer S.
LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival.
BMC Cancer. 2012 Jul 31;12(1):325.

58. Sehouli J, Runnebaum IB, Fotopoulou C, Blohmer U, Belau A, Leber H, Hanker LC, Hartmann W, Richter R, Keyver-Paik MD, Oberhoff C, Heinrich G, Dubois A, Olbrich C, Simon E, Friese K, Kimmig R, Boehmer D, Lichtenegger W, Kuemmel, S.
A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study.
Ann Oncol. 2012 Sep.;23(9):2259-64

59. Buchbender C, Kuemmel S, Hoffmann O, Stahl AR, Kimmig R, Otterbach F, Ladd S, Koeninger A, Forsting M, Bockisch A, Antoch G, Heusner TA.
FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results.
Acta Radiol. 2012 Jul 1;53(6):628-36. 2012 Jul 3.

60. Hahn S, Hecktor J, Grabellus F, Hartung V, Pöppel T, Kimmig R, Forsting M, Antoch G, Heusner TA.
Diagnostic accuracy of dual-time-point 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients.
Acta Radiol. 2012 Jun 1;53(5):518-23. 2012 Apr 30.

61. Kasimir-Bauer S, Hoffmann O, Wallwiener D, Kimmig R, Fehm T.
Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells.
Breast Cancer Res. 2012 Jan 20;14(1):R15.

62. Soliman AA, Heubner M, Kimmig R, Wimberger P.
Morbidity of inguinofemoral lymphadenectomy in vulval cancer.
ScientificWorldJournal. 2012;2012:341253


2011

63. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators.
A phase 3 trial of bevacizumab in ovarian cancer.
N Engl J Med. 2011 Dec 29;365(26):2484-96. Erratum in: N Engl J Med. 2012 Jan 19;366(3):284.

64. van der Zee AG, Colombo N, Gitsch G, Reed N, Amant F, Cibula D, Kesic VI, Kimmig R, Lopes AD, Markowska J, Marth C, Radolakis A, Salvesen H, Vaitkiene D, Verheijen RH, Zola P.
ESGO statement on the role of CA-125 measurement in follow-up of epithelial ovarian cancer.
Int J Gynecol Cancer. 2012 Jan;22(1):175.

65. Verheijen RH, Cibula D, Zola P, Reed N; council of the European Society of Gynaecologic Oncology,
Cancer antigen 125: lost to follow-up?: a European society of gynaecological oncology consensus statement.
Int J Gynecol Cancer. 2012 Jan;22(1):170-4.

66. Mikat B, Zeller A, Scherag A, Drommelschmidt K, Kimmig R, Schmidt M.
βhCG and PAPP-A in First Trimester: Predictive Factors for Preeclampsia?
Hypertens Pregnancy. 2011;31(2): 261-7

67. Sismondi P, Kimmig R, Kubista E, Biglia N, Egberts J, Mulder R, Planellas J, Moggio G, Mol-Arts M, Kenemans P.
Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients-Data from LIBERATE trial.
Maturitas. 2011 Dec;70(4):365-72.

68. Hoffmann O, Aktas B, Goldnau C, Heubner M, Oberhoff C, Kimmig R, Kasimir-Bauer S.
Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study.
Anticancer Res. 2011 Oct;31(10):3623-8.

69. Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Möbus V, Hinke A, Kümmel S, Budach V, Lichtenegger W, Schmid P.
Randomized Phase III Trial of Sequential Adjuvant Chemoradiotherapy With or Without Erythropoietin Alfa in Patients With High-Risk Cervical Cancer: Results of the NOGGO-AGO Intergroup Study.
J Clin Oncol. 2011 Oct 1;29(28):3791-7.

70. Yang W, Wagener J, Wolf N, Schmidt M, Kimmig R, Winterhager E, Gellhaus Impact of CCN3 (NOV) glycosylation on migration/invasion properties and cell growth of the choriocarcinoma cell line Jeg3.
Hum Reprod. 2011 Oct;26(10):2850-60.

71. Aktas B, Kasimir-Bauer S, Heubner M, Kimmig R, Wimberger P.
Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy.
Int J Gynecol Cancer. 2011 Jul;21(5):822-30.

72. Hoffmann O, Heubner M, Anlasik T, Winterhalter M, Dahlmann B, Kasimir-Bauer S, Kimmig R, Wohlschlaeger J, Sixt SU.
Circulating 20S Proteasome in Patients with Non-metastasized Breast Cancer.
Anticancer Res. 2011 Jun;31(6):2197-201.

73. Sauerwein W, Hoffmann O., Schütte, M., Aktas B., Abu Jawad J., Stuschke, M. Kimmig R.
Intraoperative Irradiation of the Tumor bed as a Boost in the Burst-sustaining Primary treatment of Breast cancer - Initial results and issues that arises
Strahlentherapie und Onkologie 2011;187 (Suppl.1):99-100.

74. Cibula D, Verheijen R, Lopes A, Amant F, Beller U, Colombo N, Gitsch G, Kesic V, Kimmig R, Markowska J, Marth C, Reed N, Rodolakis A, Salvesen H, Vaitkiene D, van der Zee AG, Zola P.
Training in Bowel and Upper Abdominal Surgery in Gynaecological Oncology: European Society of Gynecological Oncology (ESGO) Statement.
Int J Gynecol Cancer. 2011 Jun 28.

75. Kuhlmann JD, Schwarzenbach H, Otterbach F, Heubner M, Wimberger P, Worm KH, Kimmig R, Kasimir-Bauer S.
Loss of heterozygosity proximal to the M6P/IGF2R locus is predictive for the presence of disseminated tumor cells in the bone marrow of ovarian cancer patients before and after chemotherapy.
Genes Chromosomes Cancer. 2011 Aug;50(8):598-605.

76. Erim Y, Beckmann M, Hoffmann O, Wimberger, P., Kimmig, R.
Predictors of Psychological Stress in Breast Cancer Patients - What Should Physicians and Nursing Staff Pay Attention to in an Oncological Setting?
Geburtshilfe und Frauenheilkunde 2011 Apr.2011; 71 (4), 285-291.

77. Kimmig in: Janni W., Maass, N.
Robotic Surgery in der Gynäkologie – Chirurgie der Zukunft oder teurer PR-Gag?
Der Gynäkologe 5/2011; 401-404

78. Kurtz JE, Kaminsky MC, Floquet A, Veillard AS, Kimmig R, Dorum A, Elit L, Buck M, Petru E, Reed N, Scambia G, Varsellona N, Brown C, Pujade-Lauraine E; on behalf of Gynecologic Cancer Intergroup.
Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.
Ann Oncol. 2011 Mar 14.

79. Heubner M, Errico D, Kasimir-Bauer S, Herlyn D, Kimmig R, Wimberger P.
EpCAM-autoantibody levels in the course of disease of ovarian cancer patients.
Med Oncol. 2011 Jun;28(2):626-30.Epub 2010 Apr.

80. Wimberger P, Roth C, Pantel K, Kasimir-Bauer S, Kimmig R, Schwarzenbach H.
Impact of platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients.
Int J Cancer. 2011 Jun 1; 128(11):2572-80. 2010 Oct.

81. Heubner M, Wimberger P, Dahlmann B, Kasimir-Bauer S, Kimmig R, Peters J, Wohlschlaeger J, Sixt SU.
The prognostic impact of circulating proteasome concentrations in patients with epithelial ovarian cancer.
Gynecol Oncol. 2011 Feb;120(2):233-8.

Verbesserung der Operationsverfahren bei Krebserkrankungen zur sichereren und schonenden Behandlung.

Disseminierte Tumorzellen und CTC bei Mammakarzinom und gynäkologisch onkologische Erkrankungen.

Weiterentwicklung der medikamentösen Therapie, insbesondere Immuntherapie und Chemotherapie mit Ziel der höheren Wirkung und weniger Nebenwirkungen.

• Beckenbodensenkung
• Brustdrüsendysplasie
• Brustdrüsenentzündungen
• Brustdrüsenerkrankungen
• Brustentzündung (Mastitis)
• Brustkrebs
• Duktales Carcinoma in Situ (DCIS, Brustkrebsvorstufe)
• Eierstockkrebs
• Endometriose
• Endometriumkarzinom
• Fibroadenom (gutartiger Knoten in der Brust)
• Galaktorrhoe (Milchfluss außerhalb der Stillzeit)
• Gebärmutterhalskrebs
• Gebärmutterkrebs
• Gebärmuttersenkung
• Gynäkologische Erkrankungen
• Gynäkologisches Krebsleiden
• Harninkontinenz
• Kalk in der Brust (Mikroverkalkungen)
• Knoten in der Brustdrüse (Mastopathie)
• Mastodynie (Brustschmerzen)
• Milchgangspapillom
• Myom
• Scheidenkrebs
• Scheidenpilz
• Sexuelle Funktionsstörung
• Stuhlinkontinenz
• Vulvakarzinom
• Zyste in der Brustdrüse
• Zystozele

• Brust-Biopsie
• Brustkrebs-OP
• Brustkrebsbehandlung
• Brustrekonstruktion
• Brustwiederaufbau mit DIEP-Flap
• Endometriose-Behandlung
• Endometriose-Therapie
• Hysterektomie (Gebärmutterentfernung)
• Knotenentfernung der Brust (Exzision des Fibroadenoms)
• Myomembolisation
• Myomenukleation
• Rekonstruktive Brustchirurgie

• Brust-Biopsie
• Brustkrebsdiagnostik
• Brustkrebsvorsorge
• Brustuntersuchung (Tastuntersuchung der Brust)
• Endometriosediagnostik
• Mammasonografie
• Mammographie
• Multimodale Mammadiagnostik

• Diagnostik Mammakarzinom: Mammographie, Sonographie, Kernspintomographie
• PET-CT
• Hochgeschwindigkeits-Stanzbiopsie
• Stereotaxie
• Intraoperativer Schnellschnitt
• Intraoperative Sono- und Röntgendiagnostik
• Diagnostische Endoskopie und Staging
• 3D-4D-Ultraschall
• Doppler/Farbdoppler
• Elastographie

• Präzisionschirurgie mit daVinci-Operationsroboter
• Minimalinvasive Chirurgie mit Videolaparoskopie
• Intraoperative Bestrahlung Mammakarzinom mit Intrabeam
• Wiederherstellungsoperationen mit Lappenplastiken (TRAM, Latissimus) und Prothesenchirurgie
• Radikale therapeutische Krebschirurgie mit pelviner und paraaortaler Lymphknotenentfernung, Exenterationen mit Wiederherstellungschirurgie
• Fertilitätserhaltende Chirurgie